Abstract
Globally, about 290 000 people died from hepatitis C (HCV) in 2019, mostly from cirrhosis and hepatocellular carcinoma (HCC). Less than a decade, direct-acting antivirals (DAAs) replaced interferon-based therapies in treatment protocols and sustained virologic response (SVR) rates exceeded 95%. However, it is not clear yet whether HCV eradication by DAAs can reverse fibrosis or cirrhosis substantially, reduce the risk of developing HCC in the long term. In this review was aimed to summarizes the evidence for reversibility or progression of fibrosis following HCV clearance by DAAs, subsequently its impact on developing de nova HCC. For this purpose, cohorts in which patients achieved SVR, have paired liver stiffness measurements obtained by transient elastography were reviewed and results discussed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Academic Journal of Gastroenterology & Hepatology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
